The Rosetta Syllego System Version 1.0 Will Be Showcased at the 57th
Annual Meeting of the American Society for Human Genetics Conference in San
Diego, Calif., October 23-27
SEATTLE, October 16 /CNW/ - Rosetta Biosoftware, a leader in life science
informatics solutions, today announced that the Rosetta Syllego(TM) system has
achieved GeneChip-compatible(TM) status for use with the Affymetrix microarray
platform. This compatibility enables research organizations conducting
genome-wide association and other genetic studies to focus on revealing
genetic risk factors and therapies for diseases, such as coronary artery
disease, type 2 diabetes, and other complex diseases.
Genetic studies of complex diseases and traits pose a number of
informatics challenges that impede the accurate and reproducible
identification of genetic markers of disease and drug response. Through the
Affymetrix GeneChip Compatible Program, Affymetrix collaborates with software
developers like Rosetta Biosoftware by providing software development tools
and guidelines to conquer many of these challenges.
The Rosetta Syllego system overcomes the informatics challenges of
genetic studies by providing biologists, statistical geneticists, and
investigators responsible for generating genotyping data with tools for data
management, quality control, data analysis, and meta-analysis. The Syllego
system brings together genotyping data generated by Affymetrix and other
microarray platforms, tools for linking to analysis methods of choice, and
easy-to-use project workspaces to organize, analyze, and share data and
analysis results. The Syllego system is also a single repository for fast,
easy access to public and private genotyping data sets, reference annotation,
and non-clinical and clinical information.
"Genetic studies often generate vast quantities of data, in which lie the
keys to understanding the hereditary basis of disease," says Steve Lincoln,
Vice President of Informatics of Affymetrix. "The data management and analysis
capabilities of the Syllego system allow researchers to focus on their science
and make discoveries using these new paradigms in genetic research."
"What sets the Syllego system apart is its remarkable ability to bring
together groups of geneticists, biologists, and informaticians through the use
of a single genotyping data repository," says Yelena Shevelenko, Vice
President and General Manger of Rosetta Biosoftware. "By bringing scientists
and data together through the Syllego system, we are helping the research
community to reduce costs, accelerate discovery, and focus on the science
behind genetic studies."
The Syllego system supports the latest Affymetrix Genome-wide Human SNP
Array 6.0 and includes data analysis tools along with the ability to integrate
study data with common statistical packages, such as R. The commercial version
1.0 of the Syllego system will be showcased at a workshop at the upcoming 57th
annual meeting of the American Society for Human Genetics conference in San
Diego, Calif., on October 24. To evaluate the Syllego system, interested
parties can request a copy at: www.rosettabio.com/products/syllego/trial.
About the Rosetta Syllego System
The Rosetta Syllego system is Rosetta Biosoftware's practical solution
for genetic data management and analysis. For more information on the Syllego
system, please visit www.rosettabio.com/syllego.
About Rosetta Biosoftware
Rosetta Biosoftware is a leading provider of informatics solutions for
life science research. Its comprehensive software solutions, including the
Rosetta Resolver, Rosetta Elucidator, and Rosetta Syllego systems, empower
life scientists with advanced, scalable, and easy-to-use analysis platforms
that accelerate discovery research. Rosetta Biosoftware is a business unit of
Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc.
(NYSE: MRK). More information about Rosetta Biosoftware is available at
About the Affymetrix Developers' Network (ADN)
Through one of the largest third-party software developer communities
within the life science industry, Affymetrix works with its software
developers to provide a broad spectrum of solutions for leveraging gene
expression and genetic variation analysis in both biomedical research and
development. Membership in ADN is free of charge for both commercial and
academic software developers. For more information please visit
www.affymetrix.com/genechip/developer. View the GeneChip-compatible Software
Solutions Catalog at www.affymetrix.com/genechip/compatible.
Affymetrix GeneChip(R) microarray technology is the industry-standard
tool for analyzing complex genetic information. After inventing microarray
technology in the late 1980s, Affymetrix scientists have been dedicated to
developing innovative products that provide researchers with a more complete
view of the genome. These products continue to accelerate genetic research and
enable scientists to develop diagnostics and tailor treatments for individual
patients by identifying and measuring the genetic information associated with
Today, Affymetrix technology is used by the world's top pharmaceutical,
diagnostic and biotechnology companies, as well as leading academic,
government and not-for-profit research institutes. More than 1,600 systems
have been shipped around the world and more than 9,500 peer-reviewed papers
have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing
facilities in Sacramento, Calif., and Singapore. The company has about 1,100
employees worldwide and maintains sales and distribution operations across
Europe and Asia. For more information about Affymetrix, please visit:
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements involve risks and uncertainties, which may cause results to differ
materially from those set forth in the statements. The forward-looking
statements may include statements regarding product development, product
potential, or financial performance. No forward-looking statement can be
guaranteed, and actual results may differ materially from those projected.
Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation
to publicly update any forward-looking statement, whether as a result of new
information, future events, or otherwise. Forward-looking statements in this
press release should be evaluated together with the many uncertainties that
affect the business of Merck & Co., Inc. including, among others, the extent
to which Rosetta Inpharmatics' technology platform can be used in drug
discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics'
technologies, ability to compete against existing technologies, and those
mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the
year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form
8-K (if any) which are incorporated by reference.
Affymetrix, the Affymetrix logo and GeneChip(R) are registered trademarks
of Affymetrix, Inc. Rosetta Syllego and Syllego are trademarks of Rosetta
For further information:
For further information: Editorial Contact: For Rosetta Biosoftware:
Sasha Paegle, +1-206-926-1292 email@example.com